In December 2019, a new virus emerged in Wuhan, China rapidly becoming a pandemic with registered cases above 800,000 around the world. The virus is now known as SARS-CoV2 calling its disease coronavirus-19 or COVID-19. The mortality of the virus has been reported around 2-10% and its causes because of the proinflammatory immune response generated on the host. The cytokines involved in the immune response to COVID-19 are IL-1, IL-2, IL4, IL-6, IL-10, IL-12, IL-13, IL-17, GCSF, MCSF, IP-10, MCP-1, MIP-1α, HGF, IFN-γ y TNF-α. Ruxolitinib is an inhibitor of JAK 1/2 which is responsable for multiple cellular signals including the proinflammatory IL-6. Ruxolitinib works as and immunomodulator decreasing the cytotoxic T lymphocytes and increasing the Treg cells. This study is intended to stop the disregulated immune response caused by COVID-19 that generates the pneumonia and subsequent severe acute respiratory syndrome.

Response of C-reactive protein

description: Increment or decrease in mg/ml of C-reactive protein
time_frame: 14 days

Response of Ferritin

description: Increment or decrease in ng/ml of ferritin
time_frame: 14 days

Response of D-dimer

description: Increment or decrease in mg/ml of D-dimer
time_frame: 14 days

Rate of ICU admission

description: Requirement of Intensive Care Unit on the patients under treatment
time_frame: 14 days

Rate of mechanical ventilation

description: Requirement of mechanical ventilation on the patients under treatment
time_frame: 14 days

Overall Survival

description: Time since the diagnosis to the last follow up (recovery or death)
time_frame: 1 month

Toxicity Rate

description: Rate of adverse events associated with ruxolitinib
time_frame: 1 month ^[1]